Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 OCF Yield % is 2.18 as of Sep. 01, 2026, which is 27% above its 10-year median of 1.72. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 54.21% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for WuXi XDC Cayman's OCF Yield % or its related term are showing as below:
HKSE:02268'
s OCF Yield % Range Over the Past 10 Years
Min: 0.7 Med: 1.72 Max: 3.18
Current: 2.18
During the past 6 years, the highest OCF Yield % of WuXi XDC Cayman was 3.18%. The lowest was 0.70%. And the median was 1.72%.
HKSE:02268's OCF Yield % is ranked better than 54.21% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.1
vs HKSE:02268: 2.18
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
WuXi XDC Cayman OCF Yield % Related Terms
WuXi XDC Cayman OCF Yield % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: OCF Yield % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's OCF Yield % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a OCF Yield % of 2.18 as of Sep. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on WuXi XDC Cayman and its competitors. This is 27% above median its historical median of 1.72. Over the past decade, WuXi XDC Cayman's OCF Yield % has ranged from 0.70 to 3.18. According to the industry distribution chart, WuXi XDC Cayman ranks #98 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 45.8%.
Is WuXi XDC Cayman's OCF Yield % too high?
WuXi XDC Cayman's current OCF Yield % of 2.18 is 27% above median its 10-year median of 1.72. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 3.18. The Medical Diagnostics & Research industry median OCF Yield % is 1.10. WuXi XDC Cayman's value of 2.18 is 98.2% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #98 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #98 out of 214 companies for OCF Yield %. This puts WuXi XDC Cayman in the upper half of its industry. The industry median OCF Yield % is 1.10. WuXi XDC Cayman's value of 2.18 is 98.2% above this benchmark. Historically, WuXi XDC Cayman's own OCF Yield % has ranged from 0.70 to 3.18 over the past decade. While the company's 10-year median is 1.72 vs. the industry median of 1.10, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.10, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current OCF Yield % of 2.18 is 98.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current OCF Yield % is 2.18, which is 27% above median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current OCF Yield % of 2.18. The current OCF Yield % is 2.18, which is 27% above median its 10-year median of 1.72 and 98.2% above the Medical Diagnostics & Research industry median of 1.10. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current OCF Yield % is 2.18 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
